Noelia Tarazona, Research Fellow at Mass General Brigham Cancer Center, shared a post on LinkedIn about a recent article by V. Seguí et al. published in ESMO Open:
“New publication in ESMO Open!
This study, conducted at INCLIVA Health Research Institute, Clinical University Hospital of Valencia, led by Valentina Gambardella, Desamparados Roda Perez, highlights the crucial role of Molecular Tumor Boards in precision oncology.
- From 1,230 patients with advanced solid tumors, nearly one-third carried ESCAT II-III alterations.
- Patients receiving molecularly matched therapies in early-phase trials achieved a median OS of 31 months vs 11 months with standard approaches.
- These results underscore the need to incorporate ESCAT II-III alterations into clinical decision-making, beyond the well-established ESCAT I targets.
This work reinforces the importance of multidisciplinary collaboration and early clinical trial access to expand therapeutic opportunities for our patients. We are especially grateful for the generous donations from FERO Foundation, which made part of this research possible.”
Title: Enhancing precision oncology: the role of molecular tumor boards in early identification and targeted treatment of ESCAT II-III alterations
Authors: V. Seguí, J.A. Carbonell-Asins, J. Martín-Arana, M. García-Bartolomé, N. Grimalt, C. Martinez-Ciarpaglini, J.F. Gonzalez-Muñoz, P. Martín-Martorell, I. Gonzalez-Barrallo, A. Viala, M. Tapia, M. Huerta, G. Bruixola, A. Insa, J.M. Cejalvo, T. Fleitas, N. Tarazona, A. Cervantes, D. Roda, V. Gambardella
Read the Full Article on ESMO Open
More posts featuring Noelia Tarazona.
